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ABSTRACT
Aim: This study investigated oral immunotherapy (OIT) for children aged 6–18 years with
wheat allergies.
Methods: Well-cooked wheat spaghetti was given to 100 children with wheat allergies
every day for 17 weeks, increasing from 0.3 to 2000 mg of wheat protein, followed by
three- and nine-month maintenance phases. Blood samples were taken before therapy
and at follow-up visits. The study was carried out in 2009–2015 in four Finnish paediatric
allergology units.
Results: The children (67% male) had a mean age of 11.6 years (range 6.1–18.6), and
57 were using wheat daily 16 months after the initiation of therapy. Allergic symptoms
occurred in 94/100 children: mild in 34, moderate in 36 and severe in 24. Specific
immunoglobulin E (IgE) for x-5-gliadin was significantly higher in patients who did not
reach the target dose and were related to the intensity of reactions.
Conclusion: The majority (57%) of children with wheat allergies could use wheat in their
daily diet 16 months after the initiation of OIT, but 94/100 had adverse reactions and 60
were moderate or severe. Specific IgE to x-5-gliadin may provide a biomarker for how
much wheat can be tolerated and the intensity of the reactions to immunotherapy.
INTRODUCTION
Wheat is the major food grain in countries with mild
temperatures. Wheat-related morbidity is common and
potentially related to the specific physicochemical proper-
ties and immunogenicity of various wheat proteins (1,2).
The clinical phenotype of classical immunoglobulin E (IgE)
mediated wheat allergy varies from mild gastrointestinal
discomfort to severe life-threatening anaphylaxis (3,4).
A large number of clinical trials and a few well-designed
landmark studies have shown that oral immunotherapy
(OIT) is potentially disease-modifying treatment for milk,
egg and peanut allergies (5–7). However, the consensus that
the safety issues have been insufficiently determined, and
that there is a lack of evidence on the long-term effective-
ness of OIT has led to recommendations that this approach
to food allergies should not be routinely used in clinical
settings (8).
Little is known about OIT in patients with an IgE-
mediated wheat allergy. The initial report on wheat desen-
sitisation therapy in 2005 demonstrated successful out-
comes in a seven-year-old girl with a wheat allergy who
originally presented with abdominal pain, diarrhoea,
asthma and facial angioedema after eating wheat (9). Only
Abbreviations
IgE, Immunoglobulin E; OFC, Open oral food challenge; OIT,
Oral immunotherapy.
Key notes
 This study investigated oral immunotherapy for children
aged 6–18 years with wheat allergies.
 We found that 57/100 of the children could use wheat
in their daily diet 16 months after the initiation of oral
immunotherapy, but 94/100 had adverse reactions and
60 were moderate or severe.
 Specific immunoglobulin E to x-5-gliadin may provide a
biomarker for how much wheat can be tolerated and
the intensity of the reactions to immunotherapy.
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a few small studies on the use of OIT for children with
wheat allergies have been published since then (10–17). We
conducted a multicentre, prospective open-label study of
oral wheat immunotherapy in a series of 100 children with
an IgE-mediated allergy to wheat.
PATIENTS AND METHODS
Study population
The oral desensitisation to wheat in school-aged children
study was a prospective open-label multicentre study that
investigated oral wheat immunotherapy in children
aged 6–18 years children (ClinicalTrials.gov Identifier:
NCT01755884). The primary outcome of the study was
the number of patients who would be able to eat wheat on a
daily basis 16 months after the start of the intervention,
which comprised a 17-week build-up phase followed by
three- and nine-month maintenance phases. The secondary
outcomes were the number of patients with adverse events
during each phase of the study and the changes in the levels
of specific IgE. The study was carried out between August
2009 and February 2015 in four paediatric allergology units
in the Helsinki, Oulu, Kuopio and Tampere University
Hospitals and in one private unit at Pihlajalinna Medical
Centre, Tampere, Finland. Written informed consent was
obtained from the patients and their parents. The study
protocol was approved by the ethics committees of all the
participating centres.
A total of 100 children aged 6–18 years with a known
wheat allergy were recruited to the study. The inclusion
criteria were that they needed to be aged between six and
18 years, have a history of immediate reactions when they
ate wheat, a positive wheat-specific IgE test result
(>3.5 kU/L) and be on a diet that excluded wheat and the
related cereals of barley and rye. The diagnosis and current
immediate reactivity were confirmed with an open oral food
challenge (OFC), which was performed by attending
physicians according to the regular wheat OFC protocol
in clinical practice (18). An OFC was not performed in 13
cases, as there had been a definite, immediate reaction after
accidental wheat ingestion in the last three months before
they entered the study. The exclusion criteria were uncon-
trolled asthma or any significant systemic disease or poor
compliance.
Desensitisation protocol
The desensitisation protocol included three phases: the
build-up phase of 17 weeks, the initial maintenance phase
of three months and a long-term maintenance phase of nine
months (Fig. 1). Wheat spaghetti that had been well-
cooked, at 100°C for 15 minutes, was given to the patients
every day starting from a minimum portion of one millime-
tre of cooked spaghetti, corresponding to 0.0003 g of wheat
protein, and the dose was increased every one to two weeks
until they received 24 single strands of spaghetti measuring
24 mm each, corresponding to 2000 mg of wheat protein,
at 17 weeks. Table 1 provides the detailed desensitisation
protocol. Patients received standard doses of antihistamine
each day during the build-up phase, namely 2.5 mg of
desloratadine for children under 12 and 5 mg for children
over the age of 12, and on an as-needed basis after that. The
daily use of spaghetti or other wheat products with an
obtained maintenance dose continued for an additional
three months during the first maintenance phase. There-
after, the patients were encouraged to continue to eat wheat
products each day with no restrictions for an additional
nine months during the second maintenance phase. Clinical
follow-up visits were scheduled at three and 12 months
after reaching the maintenance dosage. The adverse reac-
tions and medication were recorded using a symptom diary
and patients contacted the study centre or local emergency
unit if they had significant reactions. Adverse events were
documented in the hospital patient records during these
personal contact visits, at the scheduled build-up visits and
at the three- and nine-month follow-up visits.
The intensity of the symptoms and the overall classifica-
tion of reactions were defined as no, mild, moderate or
severe, according to the principles of a classification system
Build-up (4 months) Maintenance 1(3 months) Maintenance 2 (9 months)
4 16 months7
Discontinuation of therapy, total n = 43
Target, n = 64
Less than
target, n = 13
Target, n = 47
Less than
target, n = 25
Target, n = 39
Less than
target, n = 18
Daily wheat dose
at the end of build-up
Daily wheat dose
at the end of maintenance
Daily wheat dose
at the end of follow-up
n = 23
n = 100 n = 77 n = 72 n = 57
n = 0 n = 5 n = 7 n = 8
0
n = 0
n = 12
Maximun wheat dose
during build-up
Target (2 g), n = 64
Less than
target, n = 36
Figure 1 Primary outcomes of the study. The diagram illustrates the course of the study, the amount of wheat tolerated and the number of the patients with successful
and unsuccessful, that is discontinuation, therapy during each phase of the study.
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proposed in 2016 (19) and taking into account those
described in the American Academy of Allergy, Asthma and
Immunology workgroup report in 2009 (20). Mild reactions
were defined as just subjective symptoms or mild objective
symptoms, including all local reactions. Moderate reactions
were defined as generalised objective symptoms with one or
more of the following – generalised urticaria or angioedema,
flushing, generalised itching, acute rhinoconjunctivitis,
moderate vomiting or acute diarrhoea – without respiratory
or cardiovascular involvement. This category also included
mild respiratory symptoms without other symptoms or
intensive subjective symptoms, such as discomfort and
stomach pain or tiredness, combined with mild or moderate
objective symptoms. Severe reactions were defined as
objective respiratory symptoms, such as extensive coughing,
inspiratory stridor or expiratory wheezing, and cardiovas-
cular symptoms such as unconsciousness, lethargy, col-
lapse, drop in blood pressure or tachycardia, alone or in
combination with other symptoms.
Blood samples and laboratory testing
Peripheral venous blood samples were taken before therapy
and at the three- and nine-month visits. Eosinophil counts,
total serum IgE levels and specific IgE to wheat, gluten and
x-5-gliadin were measured using the CAP-FEIA fluorescent
enzyme immunoassay (Thermo Fischer Scientific, Uppsala,
Sweden). Skin prick tests for wheat were carried out by
trained local laboratory personnel or nurses, using an in-
house formulated allergen of powdered whole grain wheat
diluted with 0.9% sodium chloride with 1:10 weight/
volume and a positive control of 10 mg/mL histamine
dihydrochloride (ALK-Abello, Horsholm, Denmark) (4).
Statistical evaluation
The Student’s t-test was used to analyse normally dis-
tributed continuous variables, and the Mann–Whitney U
test or Kruskal–Wallis analysis was used for skewed
distributions. Spearman’s nonparametric correlation analy-
sis was used to analyse the relationship between laboratory
parameters, age and wheat dosage. Differences in the
distribution of individuals among the groups were tested
with chi-squared statistics unless any expected value was
less than five. In those cases, Fisher’s exact test was used.
Logistic regression was used to analyse the relationship
between baseline variables, symptoms and reactions, the
achievement of target dose and discontinuation of therapy.
The Friedman test and Wilcoxon signed-rank test were used
to analyse temporal changes in laboratory parameters. A
two-tailed p value of 0.05 was considered to indicate
statistical significance. All the data were analysed using
SPSS Statistics software for Windows, version 22 (IBM
Corp, Armonk, New York, NY, USA).
RESULTS
Outcome of therapy and amount of wheat tolerated
The baseline characteristics of the patients are shown in
Table 2. The majority were male (67%), and their mean age
was 11.6 years (range 6.1–18.6). Out of the 100 patients, 77
completed the build-up phase and went on to the first three-
month maintenance phase, 72 completed that phase and
went on to the second nine-month maintenance phase and
57 patients were still using wheat daily at the end of the
study, 16 months after the intervention started (Fig. 1). We
found that 64 patients reached the target dose of 2000 mg
of wheat protein per day at the end of the 17-week build-up
period. Of the 36 patients who did not reach the target dose,
the median maximum tolerated dosage was 5.5 strands of
spaghetti, corresponding to 445 mg of wheat protein and
ranging from 1 to 1760 mg. At the end of the first, three-
month, maintenance period, 47/72 patients were still using
the target amount of 2000 mg wheat protein daily, whereas
the median daily amount of wheat consumed by the other
25/72 patients was 330 mg (range 5–1750 mg). At the end
of the second, nine-month, maintenance period, 18/57
patients still on therapy were consuming a median of
500 mg (range 83–1000 mg) wheat protein, whereas the
number of patients still eating the target amount of wheat or
more was 39/57 at the time of the final follow-up visit. Out
of these, 29 were using the target dose in the form of
spaghetti or pasta, bread, biscuits, porridge or other wheat
products, corresponding to 2000 mg of wheat protein per
Table 1 The detailed protocol for wheat desensitisation used in this study
Week
number
Daily dose of boiled wheat spaghetti
Amount of wheat
protein (mg)
Length in
millimetres
Number of
single strands of
spaghetti
1 1* 0.3
2 2* 0.7
3 3 1.0
4 4 1.4
5 5 1.7
6 10* 3.5
7 15 5.0
8 20* 7.0
9 40* 14.0
10 80 28.0
11 160 60.0
12 240, equals 1 strand 1* 80.0
13 2 170.0
14 4* 330.0
15 8 670.0
16 16* 1300.0
17 24 2000.0
The first dose of the dosage step-ups marked with an asterisk (*) was given
in the hospital outpatient clinic. All the other dosage step-ups and daily doses
occurred at home. The daily use of spaghetti or other wheat products, the
amount of wheat protein corresponding to 2000 mg in maximum,
continued with the amount of achieved maintenance dosage for an
additional three months as the first maintenance phase. Thereafter, the
patients were encouraged to continue to eat spaghetti or other wheat
products daily with no restrictions for an additional nine months as the
second maintenance phase.
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day. The remaining ten patients had more than 2000 mg of
wheat in their daily diet, varying from 3 g to no restriction,
in the form of 5–6 slices of bread, a normal size pasta meal
or other nonspecified wheat products. Reaching the target
dose or the daily amount of wheat was not related to the age
or sex of the patients (data not shown).
The initial x-5-gliadin specific IgE levels were signifi-
cantly higher in the patients who did not reach the target
dose, with a median and interquartile range (IQR) of
6.02 kU/L (2.34–16.2) versus 1.81 kU/L (0.14–7.14)
(p = 0.005). The differences were not significant for wheat
or gluten IgE (data not shown). Furthermore, 22/26 (85%)
of the patients negative for x-5-gliadin specific IgE reached
the target dose compared to 41/72 (57%) of the patients
who were initially positive for x-5-gliadin IgE (p = 0.016).
The initial skin prick test result for wheat did not differ
between subjects not reaching and reaching the target dose,
with a median (IQR) of 10 mm (5–20 mm) versus 9 mm
(IQR 5–20) (p = 0.474).
Symptoms and reactions
Only six of the 100 patients did not have any reactions
during any phase of the study, whereas 34% experienced
mild, 36% moderate and 24% severe reactions during some
phase of the study. The symptoms and reactions that
occurred in patients during each phase of the study are
shown in Table 3. We found that 70/100 (70%) patients
experienced symptoms related to wheat ingestion during
the build-up phase and these reactions were moderate or
severe in 43 (43%) patients. Similarly, symptoms occurred
in 60/77 (78%) patients during the first three-month
maintenance phase, of which 28 (35%) were moderate or
severe, and in 52/72 (72%) patients during the second nine-
month maintenance phase, of which 17 (24%) were mod-
erate or severe. The reactions were related to physical
exercise one to four hours after wheat ingestion in five
patients during the build-up phase, in two patients during
the first maintenance phase and in four patients during the
second maintenance phase. Other coexisting factors, such
as viral infections, were not recorded. We found that 12
patients used intramuscular epinephrine during the entire
study period, one of them for two separate reactions and the
remaining 11 for single reactions. In the logistic regression
analysis, the intensity of reactions at the initial food
challenge was not related to the likelihood of reaching the
target dose (data not shown), whereas the intensity of
reactions during the build-up period and the likelihood of
reaching the target dose were inversely related (Table 4A).
Of the 72 patients who successfully completed the first
maintenance phase, 30 were using antihistamine daily and
42 were only using it occasionally when they visited their
clinics at the end of this phase. The corresponding numbers
at the end of the second nine-month maintenance phase
were 8/57 for daily use and 49 for occasional use.
The initial skin prick test result or the initial levels of
wheat or gluten-specific IgE were not statistically signifi-
cantly related to the severity of reactions experienced by
each individual patient during the entire study period
(Fig. 2). In contrast, the initial x-5-gliadin specific IgE
levels were related to the intensity of reactions, in that
higher initial IgE levels were significantly associated with
Table 2 Baseline characteristics of the study population (n = 100)
Age (years), mean (range) 11.6 (6.1–18.6)
Male sex, n 67
Laboratory findings at the beginning of the study, median (range)
Total serum IgE (kU/L) (n = 95) 1096 (44–7323)
Blood eosinophils (% of leukocytes) (n = 99) 9 (2–30)
Wheat IgE (kU/L)
All patients, values at or above 100 kU/L
defined as 100 kU/L
100 (2.6–100)
Patients with defined absolute values
available (n = 76)
201 (2.6–2810)
Gluten IgE (kU/L)
All patients, values at or above 100 kU/L
defined as 100 kU/L
100 (1.8–100)
Patients with defined absolute values
available (n = 65)
146 (1.8–2610)
Omega-5-gliadin IgE (kU/L) (n = 98), absolute
values
2.9 (0–100.0)
Wheal diameter (mm) on skin prick test with
wheat, median (range) (n = 87)
10 (5–20)
Initial wheat challenge (open OFC or accidental ingestion)
Patients with OFC carried out in hospital outpatient
clinic, n (%)
87
Cumulative symptom eliciting wheat dosage
(mg), median (IQR)
300 (0.1–600)
Use of intramuscular epinephrine, n (%) 29 (35)
Patients with recent accidental ingestion (less than
three months), n (%)
13 (13)
Estimated symptom eliciting wheat dosage
(mg), median (IQR)
100 (0.1–900)
Use of intramuscular epinephrine, n (%) (data
available for 12 patients)
3 (25)
Symptoms presented during OFC or at accidental wheat ingestion (n = 100)
Subjective symptoms, n
Pruritus 12
Oral itching 64
Abdominal pain 39
Nausea, discomfort 29
Weakness, dizziness 8
Objective symptoms, n
Urticaria 42
Erythema 31
Nasal congestion and/or rhinitis 28
Conjunctival symptoms 14
Laryngeal symptoms 2
Bronchial wheezing 18
Emesis 25
Acute diarrhoea 2
Drop in blood pressure 3
Cardiovascular collapse 1
Overall classification of reaction, n
No reaction 0
Mild 15
Moderate 57
Severe 28
IQR = Interquartile range; IgE = Immunoglobulin E; OFC = Open oral food
challenge.
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more intensive reactions during some phase of the study
(Fig. 2). However, it should be noted that some patients
with very high initial levels of these antibodies only had
mild or even no reactions during the study.
Temporal changes in laboratory parameters
We had three wheat, gluten and x-5-gliadin IgE samples
available for 62, 61 and 58 patients, respectively, and these
showed that the specific IgE levels decreased significantly
as with desensitisation therapy progressed and the individ-
ual p values obtained using the Friedman test were less than
0.001 for wheat, gluten and x-5-gliadin IgE (Fig. 3).
Furthermore, when the first and second samples were
compared – namely the sample obtained before therapy and
at the end of the three-month maintenance phase or
therapy was discontinued – the decrease was only signifi-
cant for x-5-gliadin levels (p < 0.001) using the Wilcoxon
signed-rank test. However, when the samples were analysed
separately, this change was significant for those who
successfully completed the therapy (p < 0.001). There was
no significant change for any of the samples that were
available for the 27/43 subjects who discontinued the
therapy at any stage (p = 0.085).
Characteristics of the patients with unsuccessful therapy
The characteristics of the patients with positive and nega-
tive outcome are shown in Table 5. This showed that 43/
100 patients discontinued therapy at some point during the
study (Fig. 1), with 23/43 (53%) of the dropouts occurring
during the build-up phase, 5/43 (12%) during the mainte-
nance phase and 15/43 (35%) during the follow-up phase.
Of the 43 patients who discontinued the therapy, 34 (79%)
had objective or objective and subjective symptoms and
eight (16%) only had subjective symptoms. In the logistic
regression analysis, the intensity of reactions during the
initial food challenge was not related to discontinuing the
therapy (data not shown), but the likelihood of discontin-
uing the therapy was significantly increased by the intensity
of reactions during the build-up phase (Table 4B).
DISCUSSION
In this large series of children with IgE-mediated wheat
allergy, we report that 57 of 100 patients were eating wheat
daily after desensitisation therapy and follow-up, including
17 weeks of build-up and three and nine months of
maintenance. However, only 39 of these were eating the
target amount of wheat at the end of the study, namely least
2000 mg of wheat protein. Virtually all of the subjects
(94%) experienced some wheat-related allergic symptoms
during the study, and these reactions were moderate in 36%
and severe in 24% of the individual children during the
entire study period. None of the baseline characteristics
were able to identify patients who discontinued therapy
during the study. The initial levels of x-5-gliadin specific IgE
might be useful as an inverse biomarker for the amount of
wheat tolerated and for the intensity of reactions experi-
enced during OIT. Although the design of the study does
not allow us to draw any definite conclusions on the
efficacy of wheat OIT, it provides valuable data, especially
on the side-effects associated with this form of therapy for
children who are allergic to wheat.
The direct comparison of the safety and efficacy profiles
between various studies is challenging, due to variable OIT
protocols and clinical phenotype of the target populations
and between various foods. Many previous studies on OIT
Table 3 Wheat ingestion related symptoms, medication and dropouts, that is
discontinuation of therapy, during oral wheat desensitisation therapy in 100 school-
aged wheat allergic children. For patients with multiple reactions, the most intensive
reaction is reported during each phase of the study
Build-up
phase
(17 weeks)
Maintenance
phase 1
(three
months)
Maintenance
phase 2
(nine months)
Number of patients entering
the phase
100 77 72
Total number of dropouts
during the phase, n (%)
23 (23) 5 (6.6) 15 (21)
Overall classification of reactions, number of patients (%)
No reaction 30 17 (22) 20 (28)
Dropouts 1 (3.3) 0 (0) 1 (5.0)
Use of intramuscular
epinephrine
0 (0) 0 (0) 0 (0)
Mild reaction 27 32 (42) 35 (49)
Dropouts 7 (26) 0 (0) 7 (22)
Use of intramuscular
epinephrine
0 (0) 0 (0) 0 (0)
Moderate reaction 29 22 (29) 11 (15)
Dropouts 8 (29) 4 (18) 6 (33)
Use of intramuscular
epinephrine
0 (0) 2 (9.1) 1 (5.6)
Severe reaction 14 6 (7.8) 6 (8.3)
Dropouts 7 (50) 1 (17) 1 (50)
Use of intramuscular
epinephrine
6 (43) 2 (33) 2 (100)
Subjective symptoms, number of patients (%)
Pruritus 4 6 (8) 6 (8.3)
Oral itching 18 25 (32) 25 (35)
Abdominal pain 37 24 (31) 15 (21)
Nausea, discomfort 13 5 (6.5) 9 (13)
Weakness, dizziness 2 2 (2.6) 1 (1.4)
Objective symptoms, number of patients (%)
Urticaria 19 13 (17) 12 (17)
Angioedema 7 5 (6.5) 5 (6.9)
Erythema 9 5 (6.5) 5 (6.9)
Nasal congestion and/or
rhinitis
13 11 (14) 7 (9.7)
Conjunctival symptoms 4 7 (9.1) 7 (9.7)
Coughing 8 4 (5.2) 3 (4.2)
Laryngeal stridor 1 1 (1.3) 0 (0)
Bronchial wheezing 23 19 (25) 16 (22)
Emesis 13 13 (17) 3 (4.2)
Acute diarrhoea 6 1 (1.3) 0 (0)
Drop in blood pressure 0 0 (0) 0 (0)
Cardiovascular collapse 0 0 (0) 0 (0)
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for egg, milk and peanut allergies have emphasised that the
vast majority of patients only experience mild local reac-
tions (21–23). However, this might lead to a false sense of
security, as other studies have shown that moderate or
severe systemic reactions seem to be fairly common during
OIT (24,25). With regard to wheat OIT, most of the
observed reactions were mild in the Sato et al. study (15),
although three of the reactions were classified as severe
during the maintenance phase. In a Spanish study (13), two
of the six patients experienced mild adverse events during
phase when the doses were increased. Our study showed a
high rate of adverse reactions during wheat OIT, with 94/
100 of patients experienced symptoms related to wheat
consumption at some point during the study. These reac-
tions were moderate in nearly 30% and severe in nearly
15% of the patients during the build-up phase. On the other
hand, the proportion of patients with mild reactions
increased up to 40–50%, and the proportion of those with
severe reactions decreased to less than 10% during the
maintenance phases. However, having no reactions during
the build-up phase did not guarantee nonreactivity later on
maintenance, as even 80% of those 30 patients who did not
have any adverse reactions during the build-up period
experienced mild to severe reactions during the mainte-
nance phases. In our view, it seems evident that the risk of
moderate and severe allergic reactions is real and unpre-
dictable in children with IgE-mediated wheat allergy who
are receiving OIT. This risk, combined with the discomfort
related to less severe adverse events, which was sometimes
continuous, in most patients during OIT needs to be
carefully weighed against the risk, severity, anxiety and fear
of reactions related to unintentional exposure to wheat
protein while on an avoidance diet. In addition, the
comparative health-related quality of life between OIT
and avoidance should be evaluated. We are currently
planning to survey the long-term outcome of the current
Table 4 (A) Logistic regression analysis of the relation between the intensity of symptoms during the build-up phase and achievement of target dose. (B) Logistic regression
analysis of the relation between the intensity of symptoms during the build-up phase and discontinuation of the therapy at any phase
(A)
Target dose
(n = 64)
Less than target
(n = 36) OR 95% CI for OR p value
Intensity of subjective symptoms (n)
No subjective symptoms 37 10 1.00
Mild 14 5 1.32 0.38–4.55 0.659
Moderate 11 17 5.72 2.04–16.0 0.001
Intensive 2 4 7.40 1.18–46.4 0.033
Intensity of objective symptoms (n)
No objective symptoms 36 10 1.00
Mild 8 4 1.80 0.45–7.23 0.407
Moderate 16 14 3.15 1.16–8.59 0.025
Intensive 4 8 7.20 1.79–28.9 0.005
Overall classification of reactions (n)
No reaction 28 2 1.00
Mild reaction 15 12 11.20 2.21–56.8 0.004
Moderate reaction 16 13 11.38 2.27–56.9 0.003
Severe reaction 5 9 25.20 4.15–153.0 <0.001
(B)
Successful therapy
(n = 57)
Unsuccessful therapy
(n = 43) OR 95% CI for OR p value
Intensity of subjective symptoms (n)
No subjective symptoms 33 14 1.00
Mild 12 7 1.38 0.45–4.22 0.578
Moderate 11 17 3.64 1.36–9.73 0.010
Intensive 1 5 11.79 1.26–110.3 0.031
Intensity of objective symptoms (n)
No objective symptoms 29 17 1.00
Mild 8 4 0.85 0.22–3.26 0.816
Moderate 14 15 1.95 0.77–4.97 0.161
Intensive 6 6 1.71 0.47–6.14 0.414
Overall classification of reactions (n)
No reaction 23 7 1.00
Mild reaction 14 13 3.05 0.98–9.48 0.054
Moderate reaction 14 15 3.52 1.15–10.8 0.027
Severe reaction 6 8 4.38 1.13–17.0 0.033
Statistically significant p-values shown in italics.
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study population in terms of wheat use and quality of life
issues.
Previous OIT studies have shown a short-term and long-
term failure rate of 30–70% (26,27). We found that 43% of
the patients discontinued therapy at some point during the
present study. None of the demographic factors could
discriminate between those with successful and unsuccess-
ful therapy. One important factor that may lead to the
discontinuation or continuation of OIT might be the level of
motivation, especially in those not reaching the target dose.
Abdominal pain often reported during all phases of our
study is a disturbing symptom that can affect a patient’s
motivation to continue OIT. Also, the adherence to the
therapy might decrease with less frequent follow-up visits.
Another factor that could have potentially affected the
outcome of the study might be related to the form of wheat
used and the steep increasing dosing regimen used during
the build-up phase of the study, especially among the
patients with the severe phenotype. Furthermore, it is
possible that extensively cooking the spaghetti at 100°C
for 15 minutes might have changed the tolerogenic
potential of the wheat proteins and could have contributed
to the outcome of our study. It was shown in a transgenic
OVA23-3 mouse model that the intensity of heat treatment
significantly affected the allergenic properties of the antigen
and that egg white proteins aggregated markedly upon
extensive heating in retort pouch conditions (28). In our
opinion, all of these findings emphasise the currently
inadequate knowledge about how to define an optimal
OIT protocol and the successful target population for wheat
OIT.
High initial levels of specific IgE have been reported to be
related to lower tolerated doses, higher numbers and
severities of reactions and unsuccessful OIT outcomes
(24,26,29,30). An important finding in the present study
was that the initial levels of specific IgE for x-5-gliadin were
significantly higher in patients who did not reach the target
maintenance dose. Furthermore, the initial and follow-up
levels of x-5-gliadin specific IgE were related to the
intensity of objective symptoms and the severity of reac-
tions. This might have been related to the specific properties
of x-5-gliadin as an antigen (4). However, the initial or
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Figure 2 Comparison of the initial levels of allergen-specific immunoglobulin E (IgE) and skin prick test results to the intensity of the most intensive reaction in each
individual patient during the entire study period of wheat desensitisation therapy. p-Value indicates the level of significance of Kruskal–Wallis test between all the groups.
(A) Wheat-specific IgE (B) Gluten-specific IgE (C) x-5-gliadin specific IgE (D) Skin prick test. In dot plots, each dot represents single patient and the black dotted line
indicates median value.
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follow-up levels of specific IgE did not differ between those
who discontinued OIT and those who succeeded with the
therapy. The only recognisable difference was that the levels
of specific IgE only decreased significantly among those
with successful therapy. Randomised controlled studies are
needed to verify whether the stability or increase in the
component-specific IgE levels could be used as a predictive
marker of wheat OIT success.
The major limitation of the current study was the
nonrandomised, uncontrolled design. Therefore, we cannot
draw any definite conclusions on the efficacy of wheat
desensitisation therapy. However, it is very unlikely that
close to 60% of the patients would have outgrown their
wheat allergy during the short study period. For practical
reasons, the diagnosis and the initial immediate reactivity
was confirmed using an open OFC, performed by attending
physicians according to the regular wheat OFC protocol in
clinical practice, instead of using a double-blind placebo-
controlled food challenge. Furthermore, no food challenge
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Figure 3 Temporal changes in the antigen-specific immunoglobulin E (IgE)
levels among patients with all three samples available. (A) Wheat-specific IgE (B)
Gluten-specific IgE (C) x-5-gliadin specific IgE. In dot plots, each dot represents
single patient. Box plots show interquartile range and median (black line inside
the box), and the whiskers indicate 5% and 95% values. Statistical comparison
was performed using Friedman test.
Table 5 Characteristics of the patients with unsuccessful and successful therapy
Successful therapy
n = 57
Unsuccessful
therapy
n = 43 p value
Age (years), median
(range)
11.4 (6.3–16.5) 12.9 (6.1–18.6) 0.067
Male sex, n (%) 39 (68) 28 (65) 0.831
Target dose
reached during
the build-up
phase, n (%)
49 (86) 15 (35) <0.001
Reason for discontinuation of the desensitisation therapy, n (%)
Subjective
symptoms
– 8 (19)
Objective
symptoms
– 7 (16)
Subjective and
objective
symptoms
– 27 (63)
Other reason – 1 (2.3)
Intensity of the most intensive reaction during the entire study period, n (%)
No reactions 5 (8.8) 1 (2) 0.053
Mild reaction 24 (42) 10 (23)
Moderate
reaction
15 (26) 21 (49)
Severe reaction 13 (23) 11 (26)
Initial laboratory values before therapy, median (IQR)
Total serum IgE
(kU/L)
1168 (477–2249) 852 (44–5310) 0.159
Blood eosinophils
(% of leukocytes)
9 (6–13) 8.5 (2–30) 0.310
Wheat IgE (kU/L) 145 (67.9–554.59 100 (91.1–280) 0.447
Gluten IgE (kU/L) 100 (64.5–225.5) 100 (93.8–214) 0.636
Omega-5-gliadin
IgE (kU/L)
3.0 (0.2–15.4) 2.8 (1.1–8.2) 0.782
Wheal diameter on
skin prick test with
wheat (mm)
10 (8–12) 9 (7–12) 0.269
IQR = interquartile range; IgE = immunoglobulin E.
Statistically significant p-values shown in italics.
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test was performed after the therapy to define the reactivity
threshold or to test the sustained unresponsiveness after
any therapy-free period. Thus, in theory, the study popula-
tion might have included some false positive patients who
initially showed a placebo-like reactivity to wheat during
the therapy and after the maintenance. However, as stated
earlier, almost all of the patients had a previous clinical
history of severe or intensive reactivity to wheat, were
highly sensitised to wheat allergens and showed typical
subjective and objective symptoms during the initial OFC.
CONCLUSION
Nearly 60% of the children who were allergic to wheat were
able to use wheat products daily 16 months after the
initiation of OIT. However, wheat OIT was associated with
a high rate of adverse reactions, and a significant proportion
of these reactions were moderate or severe. Furthermore,
nonreactivity during the build-up phase did not guarantee
nonreactivity during the maintenance phases. Our study
showed that x-5-gliadin IgE had some potential as a
biomarker for the tolerated dose and the intensity of
reactions. Based on the results reported here, we think that
wheat OIT using cooked spaghetti is not ready for routine
clinical practice. The utility of wheat in other forms, such as
other forms of pasta, wheat bread, wheat flour and hypoal-
lergenic wheat extracts, should be investigated for OIT.
Future trials should also focus on better patient selection,
dosing protocols and adjunctive treatments in randomised
controlled studies that address the immunologic mecha-
nisms, safety and health-related quality of life issues of
wheat OIT.
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